Human evidence quality

GHK-Cu (Copper Peptide): what the human research shows

Certainty varies by clinical outcome. Each claim below is assessed on its own; open one to see the studies and the reasoning.

Research only · Last assessment published November 8, 2026 · Methodology ev-1

Evidence overview

Research volume and reviewed human evidence are different numbers, kept apart.

Indexed publications

142

Research snapshot 2026.1.1

Human clinical publications

8

PubMed records classified as human research

Distinct human studies reviewed

9

of 9 identified

Randomized controlled studies

2

among reviewed studies

Studies with reported results

8

Registered, no results available

1

Unpublished is not negative

Study results assessed for risk of bias

30

Outcomes with a certainty assessment

2

Research volume for GHK-Cu (Copper Peptide) · Library profile

Claims evaluated

Claims are things to investigate, never established benefits. Evidence for one outcome doesn’t carry over to another.

Claims evaluated for GHK-Cu (Copper Peptide)
Claim being evaluated	Eligible human studies	Certainty by outcome
Improves signs of skin aging	3	Very low certaintyAutomated, not human-reviewedWrinkles and skin quality, measured or rated(patient-important, 3 studies)
Is safe for human useSafety	5	Very low certaintyAutomated, not human-reviewedAdverse events, including skin reactions(safety, 5 studies)

Human studies

Each distinct study once, however many papers, abstracts or registrations describe it.

Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.Other design · Not reported participants · first reported 2026 · automated, not human-reviewed

Population: Human participants in a clinical study of an anti-aging face cream. Number, age, sex and skin characteristics are not described in the abstract.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Wrinkles: Serious concern (Structured limitations appraisal); Skin barrier condition: Serious concern (Structured limitations appraisal)

Full study record (PLS-00025)

Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Randomized controlled trial · Not reported participants · first reported 2006 · automated, not human-reviewed

Population: Patients meeting unspecified inclusion criteria who underwent circumoral skin resurfacing with a CO2 laser at standard settings

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Resolution of post-treatment erythema: High risk of bias (Cochrane RoB 2); Overall improvement in wrinkles: High risk of bias (Cochrane RoB 2); Overall improvement in skin appearance: High risk of bias (Cochrane RoB 2); Patient-reported improvement in overall skin quality (questionnaire): High risk of bias (Cochrane RoB 2)

Full study record (PLS-00026)

Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).Case report · 1 participants · first reported 2016 · automated, not human-reviewed

Population: One 59-year-old male with crow's feet (periorbital wrinkles).

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Periorbital wrinkles (crow's feet): Serious concern (Structured limitations appraisal); Dermal collagen on histology: Serious concern (Structured limitations appraisal); Dermal matrix proteins (collagen IV, fibrillin-1, procollagen type 1, tropoelastin): Serious concern (Structured limitations appraisal); Pain during treatment: Serious concern (Structured limitations appraisal); Adverse effects: Serious concern (Structured limitations appraisal)

Full study record (PLS-00027)

Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.Single-arm trial · Not reported participants · first reported 2025 · automated, not human-reviewed

Population: Females with acne scars

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Scar appearance (Manchester Scoring Scale): Serious concern (Structured limitations appraisal); Skin texture (smoothness, roughness, scaliness; Visioscan): Serious concern (Structured limitations appraisal); Adverse effects and in-use tolerability: Serious concern (Structured limitations appraisal)

Full study record (PLS-00028)

An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.Single-arm trial · Not reported participants · first reported 2024 · automated, not human-reviewed

Population: Adults with mild to moderate scalp dandruff / seborrheic dermatitis

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Adherent Scalp Flaking Score (ASFS): Serious concern (Structured limitations appraisal)

Full study record (PLS-00029)

The effects of hydroporation on melasma with anti-aging cocktail.Uncontrolled pilot study · Not reported participants · first reported 2017 · automated, not human-reviewed

Population: Volunteers with melasma (small group; number and characteristics not stated in abstract)

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Clinical pigmentation and erythema: Serious concern (Structured limitations appraisal); Melanin index: Serious concern (Structured limitations appraisal); Erythema index: Serious concern (Structured limitations appraisal); Dermal type IV collagen and procollagen: Serious concern (Structured limitations appraisal); p63-positive cells along basement membrane: Serious concern (Structured limitations appraisal)

Full study record (PLS-00030)

Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Randomized controlled trial · Not reported participants · first reported 1994 · automated, not human-reviewed

Population: Patients with diabetes and neuropathic (plantar) foot ulcers. All received a standardized wound care protocol: sharp debridement at entry, pressure-relieving footwear and patient education.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Percentage area closure of plantar ulcers: Some concerns (Cochrane RoB 2); Proportion of patients healing 98% or better: Some concerns (Cochrane RoB 2); Rate of ulcer closure: Some concerns (Cochrane RoB 2); Percentage area closure in larger plantar ulcers (>100 mm2 at entry): High risk of bias (Cochrane RoB 2); Incidence of ulcer infection: High risk of bias (Cochrane RoB 2)

Full study record (PLS-00031)

Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.Uncontrolled pilot study · 1,000 participants · first reported 2018 · automated, not human-reviewed

Population: Patients with male- or female-pattern hair loss, including some post-hair-transplant patients.

Assessed from the abstract only: essential methods may be missing.

Risk of bias: Hair fall on hair pull test: Serious concern (Structured limitations appraisal); Vellus hairs, terminal hairs and shaft diameter: Serious concern (Structured limitations appraisal); Patient-perceived benefit: Serious concern (Structured limitations appraisal); Total hair count: Serious concern (Structured limitations appraisal); Tolerability: Serious concern (Structured limitations appraisal)

Full study record (PLS-00032)

Topical GHK-Cu Gel for Acute Skin Wound HealingOther design · Not reported participants · first reported 2026 · automated, not human-reviewed

Population: People with acute standardized cutaneous wounds (punch-biopsy wounds); age, sex and other eligibility details not stated in the record

Full study record (PLS-00247)

Why the counts differ

Publications, studies and registrations are different units.

These numbers count different things. The research snapshot 2026.1.1 counts 8 human clinical publications: PubMed records, classified by publication type. Here, each reviewed study is counted once (9 in all), however many reports describe it (8 PubMed records, 1 registration, 0 other reports such as meeting abstracts outside PubMed).

Which source records describe which study
Study	Source record	Role
PLS-00025	PMID 42573538Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.	primary
PLS-00026	PMID 16847171Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.	primary
PLS-00027	PMID 27064823Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).	primary
PLS-00028	PMID 41001334Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.	primary
PLS-00029	PMID 39449909An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.	primary
PLS-00030	PMID 28133891The effects of hydroporation on melasma with anti-aging cocktail.	primary
PLS-00031	PMID 17147644Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.	primary
PLS-00032	PMID 29482481Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.	primary
PLS-00247	NCT07437586 · no results postedTopical GHK-Cu Gel for Acute Skin Wound Healing	registry entry

Evidence gaps

Research activity gap: No gap identified
Little indexed research of any kind.
Human research gap: No gap identified
Laboratory or animal research exists, but little human research.
Evidence quality gap: Gap identified
Human research exists, but no assessed outcome reaches moderate or high certainty.
Clinical relevance gap: No gap identified
Studies exist but none directly address a claim being evaluated.
Safety evidence gap: Gap identified
Safety is not established with moderate or high certainty for the populations, routes or durations studied.

Timeline

Registrations, publications, posted results and every change to the assessments.

1994-10-01
Published: Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.
2006-07-01
Published: Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.
2016-05-26
Published: Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).
2017-01-29
Published: The effects of hydroporation on melasma with anti-aging cocktail.
2018-02-26
Published: Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.
2024-09-24
Published: An Assessment of the Safety, Efficacy, and Tolerability of a Novel Scalp Treatment Regimen Combining a Hydroxy Acid-Based Scrub and Copper Tripeptide Serum in the Management of Seborrheic Dermatitis in Adults.
2025-08-25
Published: Efficacy and Safety Assessment of ThriveCo Scar Fader Gel With Scarcede™ in the Treatment of Skin Scars.
2026-02-27
Registered: NCT07437586
2026-08-01
Published: Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu.
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Risk-of-bias assessment published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-07
Study record published (version 1)
2026-11-08
Claim assessment published (version 1)
2026-11-08
Claim assessment published (version 1)
2026-11-08
Certainty assessment published (version 1)
2026-11-08
Certainty assessment published (version 1)
2026-11-08
Study record published (version 1)

Sources and method

Every assessment links its sources and keeps its full version history. Methodology · All assessments (CSV) · All study records (CSV)

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).